Cost-effectiveness of switching to insulin degludec from other basal insulins: evidence from Swedish real-world data (Q31152059)

29 June 2017

title

Cost-effectiveness of switching to insulin degludec from other basal insulins: evidence from Swedish real-world data (English)

1 reference

29 June 2017

3

Åsa Ericsson

1 reference

29 June 2017

author name string

Lena Landstedt-Hallin

series ordinal

1

1 reference

29 June 2017

Jens Gundgaard

series ordinal

2

1 reference

29 June 2017

Susanne Ellfors-Zetterlund

series ordinal

4

1 reference

29 June 2017

language of work or name

English

0 references

publication date

30 December 2016

1 reference

Current Medical Research and Opinion

29 June 2017

published in

1 reference

29 June 2017

volume

33

1 reference

29 June 2017

issue

4

1 reference

29 June 2017

page(s)

647-655

1 reference

A review of the pharmacological properties of insulin degludec and their clinical relevance

29 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1080/03007995.2016.1277194

Steady state is reached within 2-3 days of once-daily administration of degludec, a basal insulin with an ultralong duration of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2016.1277194

Methods and issues associated with the use of quality-adjusted life-years

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2016.1277194

The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2016.1277194

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2016.1277194

Incidence and costs of severe hypoglycaemia requiring attendance by the emergency medical services in South Central England

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2016.1277194

The psychosocial and financial impact of non-severe hypoglycemic events on people with diabetes: two international surveys

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2016.1277194

Severe hypoglycaemia in adults with insulin-treated diabetes: impact on healthcare resources

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2016.1277194

Medical resource use, disturbance of daily life and burden of hypoglycemia in insulin-treated patients with diabetes: results from a European online survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2016.1277194

The Impact of Non-Severe Hypoglycemic Events on Work Productivity and Diabetes Management

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2016.1277194

Impact of nocturnal hypoglycemic events on diabetes management, sleep quality, and next-day function: results from a four-country survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2016.1277194

Understanding the economic burden of nonsevere nocturnal hypoglycemic events: impact on work productivity, disease management, and resource utilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2016.1277194

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2016.1277194

Descriptions of health states associated with increasing severity and frequency of hypoglycemia: a patient-level perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2016.1277194

Self-report of hypoglycemia and health-related quality of life in patients with type 1 and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2016.1277194

Self-reported non-severe hypoglycaemic events in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2016.1277194

Treat-to-target trials: uses, interpretation and review of concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2016.1277194

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority tria

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2016.1277194

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority tria

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2016.1277194

Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2016.1277194

Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2016.1277194

Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2016.1277194

Cost-effectiveness of insulin degludec compared with insulin glargine in a basal-bolus regimen in patients with type 1 diabetes mellitus in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2016.1277194

Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2016.1277194

External validity of randomised controlled trials: "to whom do the results of this trial apply?".

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2016.1277194

Changes in HbA1c, insulin dose and incidence of hypoglycemia in patients with type 1 diabetes after switching to insulin degludec in an outpatient setting: an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2016.1277194

The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2016.1277194

Validation of the IMS CORE Diabetes Model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2016.1277194

A new model for 5-year risk of cardiovascular disease in Type 1 diabetes; from the Swedish National Diabetes Register (NDR)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2016.1277194

Outcomes of diabetes care: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2016.1277194

A comparison of health-related quality of life (health utility) between insulin degludec and insulin glargine: a meta-analysis of phase 3 trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2016.1277194

Risks of nontraumatic lower-extremity amputations in patients with type 1 diabetes: a population-based cohort study in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2016.1277194

Cost of hypoglycemia in patients with Type 2 diabetes in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2016.1277194

Diminishing marginal disutility of hypoglycaemic events: results from a time trade-off survey in five countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2016.1277194

Glycaemic control and incidence of heart failure in 20 985 patients with type 1 diabetes: an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2016.1277194

Development and validation of a cost-utility model for Type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2016.1277194

A Systematic Review of Cost-Effectiveness Models in Type 1 Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2016.1277194

The Cost of Diabetes-Related Complications: Registry-Based Analysis of Days Absent from Work

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2016.1277194

10.1080/03007995.2016.1277194

21 January 2018

Identifiers

DOI

1 reference

29 June 2017

1 reference